Jardiance or empagliflozin approved for the treatment of adults with chronic kidney disease in India

The approved 10 mg tablets are expected to reduce the risk of sustained decline in patients with end-stage kidney disease

February 15, 2024 07:21 pm | Updated 07:21 pm IST - NEW DELHI

File image for representation.

File image for representation. | Photo Credit: K.K. Mustafah

The Central Drugs Standard Control Organisation (CDSCO), has approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in patients with end-stage kidney disease, cardiovascular death, and hospitalisation in adults with chronic kidney disease (CKD) at risk of progression.

According to a release issued by the organisation, this indication approval allows nephrologists and cardiologists to use Jardiance 10mg tablets for the treatment of CKD in eligible patients.

“Jardiance is not recommended for the treatment of CKD in patients with polycystic kidney disease, or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease,’’ the release noted.

“We are very excited about the approval and the potential for empagliflozin to play an essential role in helping people living with kidney disease and their physicians,’’ Gagandeep Singh Bedi, managing director, Boehringer Ingelheim (India), a biopharmaceutical company which manufactures the drug, said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.